Rapt Therapeutics Inc Quick Ratio (RAPT) starting from the third quarter 2025 to third quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Rapt Therapeutics Inc   (NASDAQ: RAPT)

Rapt Therapeutics Inc 's Quick Ratio

RAPT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2025, Quick Ratio fell to 11.76 below Rapt Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 71 other companies have achieved higher Quick Ratio than Rapt Therapeutics Inc in third quarter 2025. While Quick Ratio total ranking in the third quarter 2025 has deteriorated compared to the prior quarter from 196 to 245.

Explain Quick Ratio?
How much Cash & cash equivalents RAPT´s has?
What are RAPT´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RAPT Quick Ratio (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3
Y / Y Current Liabilities Change 29.08 % -11.88 % -59 % 121.43 % -52.57 %
Y / Y Cash & cash equivalent Change 60.71 % 47.12 % 26.63 % 45.44 % -47.01 %
Quick Ratio MRQ 11.76 12.95 20.66 4.78 9.45
RAPT's Total Ranking # 245 # 196 # 36 # 311 # 298
Seq. Current Liabilities Change 2.55 % 50.3 % -82.05 % 366.62 % -29.99 %
Seq. Cash & cash equivalent Change -6.87 % -5.76 % -22.41 % 136 % -14.75 %



Quick Ratio third quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 72
Healthcare Sector # 105
Overall Market # 245


Quick Ratio Statistics
High Average Low
21.48 12.23 4.78
(Jun 30 2021)   (Dec 31 2024)




Financial Statements
Rapt Therapeutics Inc 's Current Liabilities $ 13 Millions Visit RAPT's Balance sheet
Rapt Therapeutics Inc 's Cash & cash equivalent $ 157 Millions Visit RAPT's Balance sheet
Source of RAPT's Sales Visit RAPT's Sales by Geography


Cumulative Rapt Therapeutics Inc 's Quick Ratio

RAPT's Quick Ratio for the trailling 12 Months

RAPT Quick Ratio

 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth 22.42 % 0.98 % 2.4 % 17.32 % -3.89 %
Y / Y Cash & cash equivalent TTM Growth 43.54 % 12.85 % -9.73 % -24.98 % -41.05 %
Quick Ratio TTM 8.83 8.42 7.58 6.18 7.53
Total Ranking TTM # 2699 # 2613 # 2394 # 1947 # 2981
Seq. Current Liabilities TTM Growth 3.75 % -2.14 % -13.19 % 38.9 % -14.42 %
Seq. Cash & cash equivalent TTM Growth 8.78 % 8.68 % 6.44 % 14.07 % -14.48 %

Quick ratio ranking by company, industry and sector >> Back to RAPT Financial Strength Comparisons >> Go to Compare RAPT Quick Ratio to its Competitors

On the trailing twelve months basis RAPT Cash & cash equivalent soared by 60.71 % in Q3 2025 year on year, faster than Current Liabilities, this led to increase in in Rapt Therapeutics Inc 's Quick Ratio to 8.83, Quick Ratio remained below RAPT average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 397 other companies have achieved higher Quick Ratio than Rapt Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2025 from 2613 to 2699.

Explain Quick Ratio?
How much Cash & cash equivalents RAPT´s has?
What are RAPT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 398
Healthcare Sector # 805
Within the Market # 2699


trailing twelve months Quick Ratio Statistics
High Average Low
17.69 11.05 6.18
(Mar 31 2022)   (Dec 31 2024)




Companies with similar Quick Ratio in the quarter ending Sep 30 2025, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2025 MRQ Cash & cash equivalentSep 30 2025 MRQ Current Liabilities
Upstream Bio Inc   31.28 $ 372.427  Millions$ 11.908  Millions
Repare Therapeutics Inc   30.54 $ 112.604  Millions$ 3.687  Millions
Keros Therapeutics Inc   28.78 $ 693.472  Millions$ 24.092  Millions
Contineum Therapeutics Inc   28.68 $ 182.407  Millions$ 6.361  Millions
Viking Therapeutics Inc   27.88 $ 714.570  Millions$ 25.630  Millions
Liquidia Corporation  26.17 $ 157.496  Millions$ 6.019  Millions
Edgewise Therapeutics inc   26.03 $ 563.340  Millions$ 21.646  Millions
Prothena Corporation Public Limited Company  25.09 $ 330.843  Millions$ 13.188  Millions
Immuneering Corporation  24.83 $ 227.563  Millions$ 9.164  Millions
Psyence Biomedical ltd   23.53 $ 7.150  Millions$ 0.304  Millions
Lava Therapeutics Nv  23.48 $ 99.364  Millions$ 4.231  Millions
Trevi Therapeutics Inc   22.29 $ 194.927  Millions$ 8.745  Millions
Ligand Pharmaceuticals Incorporated  21.76 $ 664.522  Millions$ 30.539  Millions
Aprea Therapeutics Inc   21.39 $ 13.718  Millions$ 0.641  Millions
Stoke Therapeutics Inc   21.34 $ 248.310  Millions$ 11.634  Millions
Cervomed Inc   20.23 $ 27.294  Millions$ 1.349  Millions
Pulmatrix Inc   19.25 $ 4.794  Millions$ 0.249  Millions
Terns Pharmaceuticals Inc   19.21 $ 295.635  Millions$ 15.387  Millions
Emmis Acquisition Corp   18.63 $ 1.446  Millions$ 0.078  Millions
Design Therapeutics Inc   18.43 $ 205.970  Millions$ 11.173  Millions
Neurogene Inc   18.04 $ 265.410  Millions$ 14.710  Millions
Climb Bio Inc   17.56 $ 86.901  Millions$ 4.949  Millions
Telomir Pharmaceuticals Inc   17.34 $ 7.329  Millions$ 0.423  Millions
Tyra Biosciences Inc   17.31 $ 274.924  Millions$ 15.879  Millions
Fulcrum Therapeutics Inc   17.25 $ 200.645  Millions$ 11.632  Millions
Ventyx Biosciences Inc   17.11 $ 192.638  Millions$ 11.259  Millions
Dianthus Therapeutics Inc   16.88 $ 402.613  Millions$ 23.855  Millions
Agios Pharmaceuticals Inc   16.78 $ 952.860  Millions$ 56.770  Millions
Arca Biopharma Inc  16.65 $ 349.155  Millions$ 20.967  Millions
Mereo Biopharma Group Plc  16.53 $ 65.859  Millions$ 3.983  Millions

Date modified: 2026-08-29T17:41:26+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.